Linked e-resources
Details
Table of Contents
Intro; Preface; Contents; Intracellular Trafficking of Gonadotropin Receptors in Health and Disease; 1 Introduction; 2 Endoplasmic Reticulum Quality Control System, Molecular Chaperones, and Regulation of Intracellular Trafficking; 2.1 Sequence Motifs That Promote/Prevent Outward Trafficking of GPCRs to the PM; 2.2 Posttranslational Modifications in GPCRs and Intracellular Trafficking; 3 Trafficking of Gonadotropin Receptors in Health and Disease; 3.1 Trafficking of Gonadotropin Receptors from the ER to the Cell Surface Plasma Membrane; 3.1.1 Sequence Motifs; 3.1.2 Glycosylation.
3.1.3 Palmitoylation3.1.4 Homo- and Heterodimerization of Gonadotropin Receptors and Trafficking; 3.2 Downward Trafficking of PM-Expressed Gonadotropin Receptors: Agonist-Stimulated Internalization and Post-Endocytic Fate; 3.3 Trafficking of Gonadotropin Receptors in Disease; 4 Conclusions; 5 Acknowledgements; References; Investigating Internalization and Intracellular Trafficking of GPCRs: New Techniques and Real-Time Experimental Approaches; 1 Introduction; 2 GPCR Signal Transduction, Desensitization, and Internalization; 3 Intracellular GPCR Signaling.
4 Therapeutic Targeting of GPCR Internalization and Intracellular Signaling5 Established Methods for Investigating GPCR Internalization; 6 Novel Real-Time Methods to Study Internalization of GPCRs; 6.1 SNAP-Tag-Based Real-Time Internalization Assay; 6.2 Alternative Real-Time Approaches to Study Receptor Internalization; 7 Future Perspectives and Concluding Remarks; References; Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors; 1 G Protein-Coupled Receptor Ligands with Original Properties; 1.1 Biased Agonists.
1.2 Pharmacological Chaperones2 The X-Linked Genetic Disease Congenital Nephrogenic Diabetes Insipidus (cNDI): The AVP V2R as a Target for PC Therapy; 2.1 The Pathology of cNDI; 2.2 Pharmacological Chaperone Treatment: Antagonists First; 3 Biased Agonist Pharmacochaperones: Ideal Therapeutics for Treating cNDI?; 3.1 Agonists Versus Antagonists; 3.2 Biased Agonists Versus Agonists; 4 Perspectives: Insights from Pharmacochaperone High-Throughput Screening Studies; 5 Conclusions; References; Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases; 1 Introduction.
3.1.3 Palmitoylation3.1.4 Homo- and Heterodimerization of Gonadotropin Receptors and Trafficking; 3.2 Downward Trafficking of PM-Expressed Gonadotropin Receptors: Agonist-Stimulated Internalization and Post-Endocytic Fate; 3.3 Trafficking of Gonadotropin Receptors in Disease; 4 Conclusions; 5 Acknowledgements; References; Investigating Internalization and Intracellular Trafficking of GPCRs: New Techniques and Real-Time Experimental Approaches; 1 Introduction; 2 GPCR Signal Transduction, Desensitization, and Internalization; 3 Intracellular GPCR Signaling.
4 Therapeutic Targeting of GPCR Internalization and Intracellular Signaling5 Established Methods for Investigating GPCR Internalization; 6 Novel Real-Time Methods to Study Internalization of GPCRs; 6.1 SNAP-Tag-Based Real-Time Internalization Assay; 6.2 Alternative Real-Time Approaches to Study Receptor Internalization; 7 Future Perspectives and Concluding Remarks; References; Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors; 1 G Protein-Coupled Receptor Ligands with Original Properties; 1.1 Biased Agonists.
1.2 Pharmacological Chaperones2 The X-Linked Genetic Disease Congenital Nephrogenic Diabetes Insipidus (cNDI): The AVP V2R as a Target for PC Therapy; 2.1 The Pathology of cNDI; 2.2 Pharmacological Chaperone Treatment: Antagonists First; 3 Biased Agonist Pharmacochaperones: Ideal Therapeutics for Treating cNDI?; 3.1 Agonists Versus Antagonists; 3.2 Biased Agonists Versus Agonists; 4 Perspectives: Insights from Pharmacochaperone High-Throughput Screening Studies; 5 Conclusions; References; Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases; 1 Introduction.